Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Novo Nordisk slashes Wegovy price for patients lacking insurance benefits
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Zacks Investment Research on MSN1d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Morgan Stanley sees ‘limited impact’ to Lilly shares from Novo CagriSema data
Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...
Hosted on MSN3d
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Novo Nordisk (NVO) on Wednesday also launched NovoCare Pharmacy to offer the company’s weight loss drugs for ...